Have a personal or library account? Click to login
Efficacy and Safety of Empagliflozine and Semaglutide (Once Weekly) in T2DM Patients in Shtip Cover

Efficacy and Safety of Empagliflozine and Semaglutide (Once Weekly) in T2DM Patients in Shtip

PRILOZI
Volume 44 (2023): Issue 1 (March 2023)
By: Valentina Velkoska Nakova,  Zoran Nakov,  Stojka Dokuzova,  Tatjana Prosheva and  Brankica Krstevska  
Open Access
|Mar 2023

Authors

Valentina Velkoska Nakova

valentina.velkovska@ugd.edu.mk

Clinical Hospital, Shtip, RN Macedonia
Faculty of medical science, University Goce Delchev, Shtip, RN Macedonia

Zoran Nakov

Faculty of medical science, University Goce Delchev, Shtip, RN Macedonia

Stojka Dokuzova

Clinical Hospital, Shtip, RN Macedonia

Tatjana Prosheva

University Clinic of Endocrinology, Diabetes and Metabolic Disease, Skopje, RN Macedonia

Brankica Krstevska

Internal Medicine Centre “Srce”, Skopje, RN Macedonia
DOI: https://doi.org/10.2478/prilozi-2023-0008 | Journal eISSN: 1857-8985 | Journal ISSN: 1857-9345
Journal RSS Feed
Language: English
Page range: 71 - 77
Published on: Mar 29, 2023
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
once weekly semaglutide,
empagliflozin,
glycosylated hemoglobin,
hospitalization
Related subjects:
Medicine,
Basic medical science,
History and ethics of medicine,
Clinical medicine,
Clinical medicine, other,
Social sciences,
Education,
Education, other

© 2023 Valentina Velkoska Nakova, Zoran Nakov, Stojka Dokuzova, Tatjana Prosheva, Brankica Krstevska, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 44 (2023): Issue 1 (March 2023)Next article